From the ∗Division of Musculoskeletal and Rheumatic Disorders. Instituto Nacional de Rehabilitacion
†Rheumatology Section, Clinic of Excellence in Rheumatology, Mexico City, Mexico
‡Center of Rheumatoid Arthritis, BIOMAB, Bogota, Colombia.
This work was partially supported by the 2016 H. Ralph Schumacher, MD/JCR/PANLAR Award to M.G.
M.G. has attended advisory board meetings, scientific consultancies and has obtained speaking fees for: AbbVie, Novartis, UCB, Esaote SpA, Janssen, Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer, and Sanofi Aventis. The remaining authors declare no conflict of interest.
Correspondence: Marwin Gutierrez, MD, PhD, Division of Musculoskeletal and Rheumatic Disorders, Instituto Nacional de Rehabilitación—“Luis Guillermo Ibarra Ibarra,” Calzada Mexico-Xochimilco 289, Colonia Arenal de Guadalupe, CP 143898, Mexico City, Mexico. E-mail: [email protected].
